Skip to main
ACXP

ACXP Stock Forecast & Price Target

ACXP Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Acurx Pharmaceuticals Inc. has received encouraging feedback from the FDA and EMA regarding its antibiotic candidate, ibezapolstat (IBZ), which has positioned the company favorably for its upcoming Phase 3 trial in adult populations. The notable antimicrobial activity and established favorable safety profile observed in patients amplify the potential for successful clinical outcomes. Additionally, the positive opinion on the company's Pediatric Investigation Plan (PIP) for the use of IBZ in children further enhances the growth prospects and market potential of Acurx's developing therapies.

Bears say

Acurx Pharmaceuticals Inc. faces significant financial hurdles due to its clinical stage status, which limits immediate revenue generation and increases the reliance on external funding to support ongoing research and development efforts. The company's focus on a niche segment of antibiotic development may heighten investor skepticism, as the competitive landscape in the biopharmaceutical industry is characterized by high failure rates and substantial regulatory challenges. Furthermore, persistent valuation concerns, compounded by operational risks and the potential for delayed product timelines, contribute to a negative outlook on the company's long-term financial viability.

ACXP has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Acurx Pharmaceuticals LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Acurx Pharmaceuticals LLC (ACXP) Forecast

Analysts have given ACXP a Strong Buy based on their latest research and market trends.

According to 1 analysts, ACXP has a Strong Buy consensus rating as of Apr 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Acurx Pharmaceuticals LLC (ACXP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.